Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Clinical treatment programs - US	$ 46	$ 21	$ 137	$ 85
Total Revenues	46	21	137	85
Costs and Expenses:
Production costs	30		30
Research and development	2,734	1,372	7,739	4,883
General and administrative	5,439	5,170	10,280	9,569
Total Costs and Expenses	8,203	6,542	18,049	14,452
Operating Loss	(8,157)	(6,521)	(17,912)	(14,367)
Loss on investments	(310)	(365)	(201)	(1,769)
Interest and other income	294	172	811	296
Gain on sale of fixed assets	39		16
Redeemable warrants valuation adjustment		1		35
Gain on sale of income tax operating losses	318	328	900	749
Net Loss	$ (7,816)	$ (6,385)	$ (16,386)	$ (15,056)
Basic loss per share	$ (0.16)	$ (0.13)	$ (0.34)	$ (0.31)
Diluted loss per share	$ (0.16)	$ (0.13)	$ (0.34)	$ (0.31)
Weighted average shares outstanding basic	48,635,165	48,079,210	48,483,802	48,036,559
Weighted average shares outstanding diluted	48,635,165	48,079,210	48,483,802	48,036,559